Plain-English translation of NCT03577041 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying three medications—Bevacizumab, Ranibizumab, and Aflibercept—that are injected directly into the eye to treat wet age-related macular degeneration (AMD), a condition where abnormal blood vessels grow under the retina and damage your central vision. Researchers want to understand which medication works best, how safe it is, and whether it provides good value for the cost in the French healthcare system. The study will also look at how these treatments affect your quality of life and daily vision.
Wet AMD can cause serious vision loss if left untreated, and doctors need better information to choose the most effective and affordable treatment for patients like you. While these three medications have all been shown to help preserve vision, doctors don't yet have clear information about which one offers the best balance of effectiveness, safety, and cost in France.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive monthly eye injections of one of the three medications for at least 3 months. Before each injection, you'll visit the clinic for an eye exam and to report any side effects or vision changes. The study will also ask you to complete surveys about your quality of life and how your vision affects your daily activities. Researchers will track your vision, safety, and overall experience to understand how well the treatment works and its impact on your life.
AI-generated summary from trial data · Jun 21, 2026 · Not medical advice
France
Sponsor
Centre Hospitalier Universitaire, Amiens
Enrollment target
~600 participants
Started
January 2020
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sophie BRYSELBOUT, Dr
CHU Amiens
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.